Search
nabilone (Cesamet)
Tradename: Cesamet, DEA-controlled substance: class 2
Indications:
- 2nd line agent for nausea/vomiting from chemotherapy
- may improve symptoms of agitation & aggression among patients with Alzheimer's disease* [2]
- may improve anxiety & sleep disorders in Parkinson disease [3]
* see psychosis & agitation in the elderly
Pregnancy category C
Dosage: 1-2 mg PO BID-TID
Tabs: 1 mg (bottles of 20)
Adverse effects:
1) orthostatic hypotension
2) dizziness
3) drowsiness
4) dry mouth
5) euphoria
6) coordination disturbance
Drug interactions:
1) may produce additive effects with CNS depressants
- alcohol, benzodiazepines, barbiturates
2) may displace highly protein bound drugs
3) may cause additive tachycardia &/or hypertension when used in combination with anticholinergics, tricyclic antidepressants, or sympathomimetic agents
Mechanism of action:
- interaction with cannabinoid receptor(s) in CNS
Interactions
drug adverse effects of psychotropic agents
General
anti-emetic
cannabinoid (spice, K2, AMB-FUBINACA)
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 13(8): 2006
New Drug: Cesamet (Nabilone)
Detail-Document#: 220813
(subscription needed) http://www.prescribersletter.com
- Monaco K
Nabilone Effective for Easing Agitation in Alzheimer's -
Cognition, neuropsychiatric symptoms also improved with synthetic
cannabinoid.
MedPage Today. July 25, 2018
https://www.medpagetoday.com/meetingcoverage/aaic/74214
- Lanctot K, et al
Nabilone significantly improves agitation/aggression in patients
with moderate-to-severe AD: Preliminary results of a placebo-
controlled, double-blind, cross-over trial.
Alzheimer's Association International Conference (AAIC) 2018;
Abstract F4-02-04.
- Peball M, Krismer F, Knaus HG et al.
Non-motor symptoms in Parkinson's disease are reduced by nabilone.
Ann Neurol 2020 Aug 5; [e-pub]
PMID: 32757413
https://onlinelibrary.wiley.com/doi/10.1002/ana.25864
- Valeant Pharmaceuticals International
http://www.valeant.com